BioCentury on BioBusiness,
Table: EPS watch
Back to the parent article
Monday, February 3, 2014
At least 20 biotechs and pharmas reported earnings
last week. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) was up 19%, adding
nearly $5 billion in market value last week, after beating the Street's revenue
and EPS estimates. The company, which markets rare blood disorder drug Soliris
eculizumab, also guided to a lower 2014 non-GAAP tax rate than had been
modelled by analysts.
Fellow large-cap biotech Celgene Corp.
(NASDAQ:CELG) lost $3.8 billion in market value last week. The company
announced EPS that missed the consensus estimate and 2014 EPS and revenue
guidance below analyst estimates. Also last week, researchers from Memorial
Sloan Kettering Cancer Center questioned the risk-benefit profile of Celgene's
Abraxane nab-paclitaxel in comparison to the added cost of its use in
pancreatic cancer patients in a letter to the editor in the New England
Journal of Medicine. Celgene also disclosed that FDA accepted for review an
application for Otezla apremilast to treat moderate to severe psoriasis, with a
Sept. 23 PDUFA date (see B12).
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]